Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8867-8875

  Berger, Raanan ^a,c,f   Febbo, Phillip G ^a,b,c,f   Majumder, Pradip K ^a   Zhao, Jean J ^a   Mukherjee, Shayan ^d   Signoretti, Sabina ^b,c   Campbell, K Thirza ^a   Sellers, William R ^a,b,c,d   Roberts, Thomas M ^a,d   Loda, Massimo ^b,c   Golub, Todd R ^a,d,e   Hahn, William C ^a,b,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f Inst Genome Sci Plcy Duke U   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; TESTOSTERONE;

ANDROGEN ABLATION THERAPY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER HORMONE THERAPY; CARCINOGENICITY; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; HUMAN PROSTATE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION;

ANDROGENS; ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENES, RAS; HUMANS; MALE; MICE; MULTIGENE FAMILY; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TELOMERASE;

EID: 10844295905     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2938     Document Type: Article

References (62)

1. Coffey DS, Isaacs JT. Control of prostate growth. Urology 1981;17:17-24.
2. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002;60:132-8; discussion 138-9.
3. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
4. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
5. Navone NM, Logothetis CJ, von Eschenbach AC, et al. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 1998;17:361-71.
6. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: past, present and future. Semin Cancer Biol 2001;11:245-60.
7. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
8. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
9. Kaighn M, Narayan K, Ohnuki Y, et al. Establishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
10. Stone K, Mickey D, Wunderli H, et al. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-81.
11. Weijerman PC, Romijn HC, Peehl DM. Human papilloma virus type 18 DNA immortalized cell lines from the human prostate epithelium. Prog Clin Biol Res 1994;386:67-9.
12. Weijerman PC, Konig JJ, Wong ST, et al. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994;54:5579-83.
13. Bright RK, Vocke CD, Emmert-Buck MR, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997;57:995-1002.
14. Roy-Burman P, Wu H, Powell WC, et al. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004;11:225-54.
15. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
16. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15:50-65.
17. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002;21:4577-86.
18. Rich JN, Quo C, McLendon RE, et al. A genetically tractable model of human glioma formation. Cancer Res 2001;61:3556-60.
19. MacKenzie KL, Franco S, Naiver AJ, et al. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 2002;21:4200-11.
20. Yu J, Boyapati A, Rundell K. Critical role for SV40 small-t antigen in human cell transformation. Virology 2001;290:192-8.
21. Zhao JJ, Gjoerup OV, Subramanian RR, et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003;3:483-95.
22. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002;9:601-10.
23. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
24. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-6.
25. Li C, Wong WH, Model-based analysis of oligonucleotide arrays: model validation, design issues, and standard error application. Genome Biol 2001;2:32.1-32.11.
26. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
27. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73.
28. Kiyono T, Foster SA, Koop JI, et al. Both Rb/p161NK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998;396:84-8.
29. Dickson MA, Hahn WC, Ino Y, et al. Human keratinocytes that express hTERT and also evade a p16ink4a-enforced lifespan limit become immortal while retaining normal growth and differentiation characteristics. Mol Cell Biol 2000;20:1436-47.
30. Henke RP, Kruger E, Ayhan N, et al. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 1994;152:1297-301.
31. Voeller HJ, Sugars LY, Pretlow T, et al. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994;151:492-5.
32. Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-6.
33. Phillips SM, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-7.
34. Moul JW, Friedrichs PA, Lance RS, et al. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992;20:327-38.
35. Jenkins RB, Qian J, Lieber MM, et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-31.
36. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
37. Garraway LA, Lin D, Signoretti S, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003;55:206-18.
38. Sweat SD, Pacelli A, Bergstralh EJ, et al. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 1999;161:1229-32.
39. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
40. Cunha GR, Hayward SW, Wang YZ. Role of stroma in carcinogenesis of the prostate. Differentiation 2002;70:473-85.
41. Craft N, Shostak Y, Carey M, et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;5:280-5.
42. Nakahara M, Fukushima M, Tachyo T, et al. Establishment of a SV40-transformed cell line from primary culture of rat dorsolateral prostatic epithelial cells. Exp Cell Res 1990;190:271-5.
43. Bello D, Webber MM, Kleinman HK, et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215-23.
44. Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998;78:319-33.
45. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61:8135-42.
46. Di Cristofano A, De Acetis M, Koff A, et al. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-4.
47. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
48. Wang S; Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-21.
49. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci USA 2003;100:7841-6.
50. Anwar K, Nakakuki K, Shiraishi T, et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992;52:5991-6.
51. Konishi N, Hiasa Y, Tsuzuki T, et al. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997;30:53-7.
52. Berthon P, Waller AS, Villette JM, et al. Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int J Cancer 1997;73:910-6.
53. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
54. Hayward SW, Rosen MA, Cunha GR. Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol 1997;79(Suppl 2):18-26.
55. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17:279-84.
56. Cunha GR, Hayward SW, Wang YZ, et al. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003;107:1-10.
57. Stanbrough M, Leav I, Kwan PW, et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001;98:10823-8.
58. Weinstein IB. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63-4.
59. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-72.
60. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
61. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
62. Huettner CS, Zhang P, Van Etten RA, et al. Reversibility of acute B-cell leukaemia induced by BCR-ABLI. Nat Genet 2000;24:57-60.